2025
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
Siegal D, Tseng E, Schünemann H, Angchaisuksiri P, Cuker A, Dane K, DeSancho M, Diuguid D, Griffin D, Klok F, Lee A, Neumann I, Pai A, Righini M, Sanfilippo K, Terrell D, Akl E, Al Jabiri R, Al Jabiri Y, Barbara A, Bognanni A, Akl I, Boulos M, Brignardello-Petersen R, Chan M, Charide R, Colunga-Lozano L, Dearness K, Darzi A, Hussein H, Karam S, Kolb P, Mansour R, Morgano G, Morsi R, Muti-Schünemann G, Nadim M, Noori A, Philip B, Piggott T, Qiu Y, Benitez Y, Schünemann F, Stevens A, Solo K, Wiercioch W, Mustafa R, Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances 2025, 9: 1247-1260. PMID: 39437797, DOI: 10.1182/bloodadvances.2024014219.Peer-Reviewed Original ResearchConceptsCOVID-19-related critical illnessConditional recommendationAcute illnessHealth care professionalsAmerican Society of HematologyProphylactic-intensity anticoagulationCritical illnessEvidence-based recommendationsVenous thromboembolismRandomized controlled trialsCare professionalsPatient representativesRisk of venous thromboembolismGuideline developmentRecommendations AssessmentTherapeutic-intensity anticoagulationExecutive summaryLiving guidelinesMultidisciplinary panelIncreased risk of venous thromboembolismSystematic reviewAssessed certaintyCOVID-19-relatedControlled trialsMcMaster UniversityDeucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Paul C, Papp K, Colombo M, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Thaçi D, Strober B. Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials. Journal Of The European Academy Of Dermatology And Venereology 2025 PMID: 40045918, DOI: 10.1111/jdv.20553.Peer-Reviewed Original ResearchLong-term extension trialsLong-term extensionModerate to severe plaque psoriasisSevere plaque psoriasisPlaque psoriasisAdverse eventsTyrosine kinase 2Person yearsData cut-offYear of treatmentAdverse cardiovascular eventsTreatment of adultsPatient-reported outcomesSystemic therapyHerpes zosterSafety profileVenous thromboembolismDeucravacitinibCardiovascular eventsEfficacy resultsPatientsPsoriasisOutcome ratesExtension trialParent trialPredictors of Venous Thromboembolism Following Geriatric Distal Femur Fracture Fixation: Are These Patients at Higher Risk Compared With Hip Fracture Patients?
Seddio A, Vasudevan R, Gouzoulis M, Jabbouri S, Grauer J, Fram B. Predictors of Venous Thromboembolism Following Geriatric Distal Femur Fracture Fixation: Are These Patients at Higher Risk Compared With Hip Fracture Patients? JAAOS Global Research And Reviews 2025, 9: e24.00246. PMID: 39823200, PMCID: PMC11745856, DOI: 10.5435/jaaosglobal-d-24-00246.Peer-Reviewed Original ResearchConceptsOdds of venous thromboembolismDirect oral anticoagulantsVenous thromboembolismHeightened oddsHFx patientsIncreased odds of VTEPredictors of venous thromboembolismRisk factors of venous thromboembolismIncidence of venous thromboembolismRate of venous thromboembolismAssociated with considerable morbidityAssociated with reduced oddsFactors of venous thromboembolismEffective therapeutic optionIndependent risk factorClinical risk factorsHip fracture patientsRetrospective cohort studyFemur fracture fixationCoagulopathy disordersOral anticoagulantsElixhauser Comorbidity IndexSurgical managementActive cancerDistal femur fracture fixationIntercontinental variations in the presentation and management of venous thromboembolism
Chaar C, Chan S, Lee A, Bikdeli B, Tiberio G, Chopard R, Weinberg I, Yamashita Y, Nikandish R, Monreal M. Intercontinental variations in the presentation and management of venous thromboembolism. JVS-Vascular Insights 2025, 3: 100201. DOI: 10.1016/j.jvsvi.2025.100201.Peer-Reviewed Original ResearchManagement of venous thromboembolismVenous thromboembolismPulmonary embolismLow-risk pulmonary embolismTreatment modalities of patientsOpen pulmonary embolectomyVenous thromboembolism presentationHigh-risk PEIntermediate-risk PELow-molecular-weight heparinLower body mass indexVitamin K antagonistsSystemic thrombolytic therapyProportion of patientsVenous thromboembolism patientsBody mass indexCoronary artery diseaseTreatment of PEPulmonary embolectomyK antagonistsOral anticoagulantsProximal DVTActive cancerOutpatient anticoagulationEndovascular treatment
2024
Venous Thromboembolism Prophylaxis in Pregnancy: Why are the U.S. and European Guidelines so Different? Recent Studies and Clinical Insights
Piacquadio M, Paidas M. Venous Thromboembolism Prophylaxis in Pregnancy: Why are the U.S. and European Guidelines so Different? Recent Studies and Clinical Insights. Current Obstetrics And Gynecology Reports 2024, 14: 3. DOI: 10.1007/s13669-024-00407-9.Peer-Reviewed Original ResearchLow-molecular-weight heparinVenous thromboembolism prophylaxisVenous thromboembolismObstetric patientsEuropean guidelinesPostpartum periodHospitalized obstetric patientsMolecular weight heparinMechanical VTE prophylaxisVTE risk stratificationRandomized controlled studyObstetric populationPregnant populationRisk stratificationThromboembolism prophylaxisVTE prophylaxisInstitutional protocolMechanical prophylaxisWeight heparinProphylaxisAnticoagulant agentsPregnancyPoor adherenceControlled studiesPatientsDeucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s423. DOI: 10.25251/skin.8.supp.423.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateParent trialAdverse cardiovascular eventsTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsCardiovascular eventsSafety signalsPatientsResponse rateIncidence ratePsoriasisAnticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
Azzam M, Kawtharany H, Monagle P, Bercovitz R, Hamarsha Q, Alkhader A, Abou Zeid H, Mansour R, Patel P, Tabak C, Baghdadi S, Betensky M, Bhat R, Biss T, Branchford B, Brandao L, Chan A, Faustino E, Jaffray J, Jones S, Kerlin B, Kucine N, Kumar R, Male C, Pelland-Marcotte M, Raffini L, Raulji C, Sartain S, Takemoto C, Tarango C, Van Ommen H, Velez-Yanguas M, Vesely S, Wiernikowski J, Williams S, Wilson H, Woods G, Zia A, Mustafa R. Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis. Blood 2024, 144: 1257-1257. DOI: 10.1182/blood-2024-212150.Peer-Reviewed Original ResearchRisk of biasCertainty of evidenceVenous thromboembolismPediatric patientsThrombus resolutionAll-cause mortalityThrombus recurrenceAC therapyAnticoagulant therapyAbsolute effectEvents of all-cause mortalityPediatric populationSystematic reviewNon-randomized Studies of InterventionsManagement of venous thromboembolismMeta-analysisStudies of interventionsConcerns related to riskNon-randomized observational studyNon-randomized studiesRecommendations AssessmentThrombus progressionBleeding eventsBleeding riskPortal hypertensionImproved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: A promising new addition to preoperative optimization
Seddio A, Wilhelm C, Gouzoulis M, Islam W, Vasudevan R, Halperin S, Rubin L, Medvecky M, Donohue K, Grauer J. Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: A promising new addition to preoperative optimization. JSES International 2024 DOI: 10.1016/j.jseint.2024.10.006.Peer-Reviewed Original ResearchTotal shoulder arthroplastyBody mass indexT2DM patientsElixhauser Comorbidity IndexMultivariate analysisOdds of surgical site infectionUrinary tract infectionSurgical site infectionAcute kidney injuryType II diabetes mellitusII diabetes mellitusTract infectionsSite infectionClinical benefitPreoperative optimizationCardiac eventsKidney injuryVenous thromboembolismMetformin useAdverse eventsManagement of type II diabetes mellitusMass indexDiabetes mellitusType II diabetesAdverse outcomesOutcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis
Al Kasab S, Almallouhi E, Shu L, Kicielinski K, Salehi Omran S, Liebeskind D, Zubair A, Vedovati M, Paciaroni M, Antonenko K, Heldner M, de Havenon A, Henninger N, Yaghi S. Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis. Neurology Clinical Practice 2024, 15: e200381. PMID: 39399562, PMCID: PMC11464219, DOI: 10.1212/cpj.0000000000200381.Peer-Reviewed Original ResearchRisk of recurrent venous thromboembolismRecurrent venous thromboembolismCerebral venous thrombosisVenous thromboembolismFemale patientsVenous thrombosisBaseline characteristicsOutcome of cerebral venous thrombosisRate of recurrent venous thromboembolismProvoking factorsRare cause of strokeTransient provoking factorsKaplan-Meier survival analysisDuration of anticoagulationOutcomes of patientsMann-Whitney <i>Cause of strokeConsecutive patientsRare causeRecurrence rateMale patientsMulticenter studyRetrospective databaseStandard treatmentCox regressionCancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Streiff M, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin K, Fogerty A, Crestani N, Gangaraju R, Rojas-Hernandez C, Goldhaber S, Ibrahim I, Kubal T, Leavitt A, Lim M, Mann J, Mantha S, Morton C, Nester A, O'Brien A, Ortel T, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 483-506. PMID: 39236759, DOI: 10.6004/jnccn.2024.0046.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesNCCN GuidelinesClinical practice guidelinesVenous thromboembolismVenous thromboembolic diseaseNCCN panelCancer-associated venous thromboembolismInternal medicinePractice guidelinesMedical oncologyThromboembolic diseaseTreatment of venous thromboembolismNCCNLife-threatening conditionMultidisciplinary effortRecommended treatment optionGuidelinesOncologyAdult patientsTreatment optionsInterventional radiologyDiverse subtypesCancerPatientsPreventionHereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network
DeSancho M, Suvar E, Roberts J, Tarantino M, Schwartz J, Callis J, Recht M. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal Of Thrombosis And Haemostasis 2024, 22: 3183-3190. PMID: 39151704, DOI: 10.1016/j.jtha.2024.07.026.Peer-Reviewed Original ResearchConceptsHereditary antithrombin deficiencyLow-molecular-weight heparinVenous thromboembolismOral anticoagulantsAT concentrateAdverse eventsIncreased risk of venous thromboembolismRisk factorsRisk of venous thromboembolismDirect oral anticoagulantsAmerican ThrombosisSeventy-nine patientsDeep vein thrombosisHemostasis NetworkRecurrent thrombosisConcentrate administrationPulmonary embolismAntithrombin deficiencyThrombotic eventsVein thrombosisProspective studyPredominant manifestationArterial thrombosisGlobal RegistryIncreased riskDeucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s406. DOI: 10.25251/skin.8.supp.406.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsSafety signalsPatientsContinuous treatmentResponse rateIncidence rateParent trialPsoriasisAllosteric TYK2 inhibitorScreening and Prophylaxis for Venous Thromboembolism in Pediatric Surgery: A Systematic Review
Kelley-Quon L, Acker S, St Peter S, Goldin A, Yousef Y, Ricca R, Mansfield S, Sulkowski J, Huerta C, Lucas D, Rialon K, Christison-Lagay E, Ham P, Rentea R, Beres A, Kulaylat A, Chang H, Polites S, Diesen D, Gonzalez K, Wakeman D, Baird R. Screening and Prophylaxis for Venous Thromboembolism in Pediatric Surgery: A Systematic Review. Journal Of Pediatric Surgery 2024, 59: 161585. PMID: 38964986, DOI: 10.1016/j.jpedsurg.2024.05.015.Peer-Reviewed Original ResearchIncidence of venous thromboembolismVenous thromboembolismPharmacological prophylaxisSystematic reviewUltrasound screeningEpidemiology of venous thromboembolismAmerican Pediatric Surgical Association OutcomesPreferred Reporting ItemsStudy systematically reviewsLow-molecular-weight heparinRoutine ultrasound screeningCongenital heart diseasePediatric trauma populationPediatric surgical populationBody mass indexPediatric surgical patientsMolecular weight heparinSequential compression devicesInjury Severity ScoreCentral line placementSpinal cord injuryInflammatory bowel diseaseWeb of Science databasesLength of stayReporting ItemsTotal Hip Arthroplasty in Patients Who Have Factor V Leiden: Elevated Risks Isolated to Venous Thromboembolism Events
Sanchez J, Jiang W, Dhodapkar M, Radford Z, Rubin L, Grauer J. Total Hip Arthroplasty in Patients Who Have Factor V Leiden: Elevated Risks Isolated to Venous Thromboembolism Events. The Journal Of Arthroplasty 2024, 39: 2421-2426. PMID: 38838962, DOI: 10.1016/j.arth.2024.05.083.Peer-Reviewed Original ResearchFactor V LeidenAdverse eventsChemoprophylactic agentV LeidenMultivariate analysisFactor V Leiden patientsTotal hip arthroplastyPatients to venous thromboembolismLog-rank testIncreased VTE riskVenous thromboembolic eventsElevated riskPerioperative adverse eventsPre-existing comorbiditiesAdministrative claims databaseInherited thrombophiliaThromboembolic eventsElixhauser Comorbidity IndexAdult patientsVenous thromboembolismImplant survivalVTE riskComorbidity indexClaims databaseHip arthroplastyCerebral venous sinus thrombosis associated with cancer: analysis of the ACTION-CVT study
Vedovati M, Shu L, Henninger N, Zubair A, Heldner M, Al Kasab S, Siegler J, Liebeskind D, Antonenko K, Yaghi S, Paciaroni M. Cerebral venous sinus thrombosis associated with cancer: analysis of the ACTION-CVT study. Journal Of Thrombosis And Thrombolysis 2024, 57: 1008-1017. PMID: 38824485, PMCID: PMC11315801, DOI: 10.1007/s11239-024-02997-w.Peer-Reviewed Original ResearchCases of cerebral vein thrombosisVenous thromboembolismRisk of recurrent venous thromboembolismRadiological characteristics of patientsCerebral vein thrombosisRecurrent venous thromboembolismKaplan-Meier methodLog-rank testAbsence of headacheAll-cause-deathLogistic regression analysisCharacteristics of patientsCancer statusCohort studyPropensity score matchingConsecutive patientsAssociated with cancerRadiological characteristicsVein thrombosisStudy outcomesRecanalization rateOlder ageRisk factorsMultivariate analysisPatient managementRole of Vena Cava Filter in the Prophylaxis and Treatment of Venous Thromboembolism in Injured Adult Patients: A Systematic Review, Meta-Analysis, and Practice Management Guideline from the Eastern Association for the Surgery of Trauma [RETRACTED].
Bhattacharya B, Kodadek L, Nichiporenko I, Morrissey S, Kirsch J, Choi J, Ladhani H, Kasotakis G, Mukherjee K, Narsule C, Sharma R, Ruangvoravat L, Grushka J, Rattan R, Bugaev N. Role of Vena Cava Filter in the Prophylaxis and Treatment of Venous Thromboembolism in Injured Adult Patients: A Systematic Review, Meta-Analysis, and Practice Management Guideline from the Eastern Association for the Surgery of Trauma [RETRACTED]. Journal Of Trauma And Acute Care Surgery 2024 PMID: 38454308, DOI: 10.1097/ta.0000000000004289.Peer-Reviewed Original ResearchInferior vena cava filterInferior vena cavaQuality of evidenceDeep vein thrombosisInjured adult patientsRandomized controlled trialsVenous thromboembolismInjured patientsIVC filtersPulmonary embolismAdult patientsInferior vena cava filter useMeta-analysisEastern Association for the Surgery of TraumaTreatment of venous thromboembolismEvidence-based guidelinesPlacement of IVC filtersSystematic review/meta-analysisAcute venous thromboembolismVena cava filterPrevent venous thromboembolismPractice management guidelinesSurgery of TraumaLength of stayRecommendations AssessmentFactor XI: structure, function and therapeutic inhibition
Ali A, Becker R. Factor XI: structure, function and therapeutic inhibition. Journal Of Thrombosis And Thrombolysis 2024, 57: 1315-1328. PMID: 38622277, PMCID: PMC11645426, DOI: 10.1007/s11239-024-02972-5.Peer-Reviewed Original ResearchFactor XI inhibitorsVitamin K antagonistsEnd-stage renal diseaseFactor XITraditional anticoagulantsSafety profileInherent risk of bleedingPhase 3 clinical trialsPhase 2 studyMultiple coagulation factorsRisk of bleedingFactor XI deficiencyIntrinsic pathway of coagulationPathway of coagulationFXI inhibitorsK antagonistsOral anticoagulantsAnticoagulant therapyTherapeutic anticoagulationVenous thromboembolismPreclinical studiesAtrial fibrillationClinical endpointsRenal diseaseClinical trialsPropensity weighted analysis of chemical venous thromboembolism prophylaxis agents in isolated severe traumatic brain injury: An EAST sponsored multicenter study
Ratnasekera A, Seng S, Kim D, Ji W, Jacovides C, Kaufman E, Sadek H, Perea L, Poloni C, Shnaydman I, Lee A, Sharp V, Miciura A, Trevizo E, Rosenthal M, Lottenberg L, Zhao W, Keininger A, Hunt M, Cull J, Balentine C, Egodage T, Mohamed A, Kincaid M, Doris S, Cotterman R, Seegert S, Jacobson L, Williams J, Moncrief M, Palmer B, Mentzer C, Tackett N, Hranjec T, Dougherty T, Morrissey S, Donatelli-Seyler L, Rushing A, Tatebe L, Nevill T, Aboutanos M, Hamilton D, Redmond D, Cullinane D, Falank C, McMellen M, Duran C, Daniels J, Ballow S, Schuster K, Ferrada P. Propensity weighted analysis of chemical venous thromboembolism prophylaxis agents in isolated severe traumatic brain injury: An EAST sponsored multicenter study. Injury 2024, 55: 111523. PMID: 38614835, DOI: 10.1016/j.injury.2024.111523.Peer-Reviewed Original ResearchConceptsVenous thromboembolism prophylaxis initiationLow-molecular-weight heparinVenous thromboembolism prophylaxisChemical venous thromboembolism prophylaxisVenous thromboembolismIsolated severe traumatic brain injuryUnfractionated heparinSevere traumatic brain injuryNeurosurgical interventionTraumatic brain injuryVTE prophylaxis agentLow-molecular-weight heparin injectionsLow-molecular-weight heparin groupPropensity weighted analysisVenous thromboembolic eventsCox proportional hazards modelsMolecular weight heparinMulti-center analysisYears of ageProportional hazards modelStatistically significant differenceII trauma centerSubcutaneous UHThe National Healthcare Safety Network’s digital quality measures: CDC’s automated measures for surveillance of patient safety
Shehab N, Alschuler L, McILvenna S, Gonzaga Z, Laing A, deRoode D, Dantes R, Betz K, Zheng S, Abner S, Stutler E, Geimer R, Benin A. The National Healthcare Safety Network’s digital quality measures: CDC’s automated measures for surveillance of patient safety. Journal Of The American Medical Informatics Association 2024, 31: 1199-1205. PMID: 38563821, PMCID: PMC11031211, DOI: 10.1093/jamia/ocae064.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkFast Healthcare Interoperability ResourcesPublic health surveillancePatient safetyHealth surveillanceHealthcare facility-onset Clostridioides difficile infectionPrevent patient harmQuality measuresBurden of reportingImprove data collectionPatient harmInteroperability ResourcesPublic healthSafety NetworkHealthData collectionValidity of dataClostridioides difficile infectionVenous thromboembolismCollaborative programSurveillanceNationalHealthcareHarmIncreasing speedDeucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Berger V, Vritzali E, Hoyt K, Colombo M, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s366. DOI: 10.25251/skin.8.supp.366.Peer-Reviewed Original ResearchModified nonresponder imputationPlaque psoriasisModerate to severe plaque psoriasisDiscontinuations due to AEsExposure-adjusted incidence ratesSevere plaque psoriasisParent trialAdverse cardiovascular eventsLong-term extensionTreatment of adultsSystemic therapyNonresponder imputationEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismDeucravacitinibCardiovascular eventsEfficacy resultsPatientsResponse rateIncidence ratePsoriasisAllosteric TYK2 inhibitorEfficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply